Email this article First report of observation trial about impact of bisphosphonate`s treatment to the quality of life breast cancer patient with bone metastases
- Authors: Zelenova O.V.1, Bolotina L.V.2, Nikitina L.Y.3, Chernikov M.V.4
-
Affiliations:
- Central Research Institute for Organization and Informatization of Health Care, Russian Ministry of Health
- P.A. Herzen Moscow Oncology Research Institute
- Orenburg Regional Clinical Oncology Dispensary
- AO Aston Consulting, Moscow
- Issue: No 2 (2012)
- Pages: 82-88
- Section: PHARMACOTHERAPY
- Published: 23.05.2012
- URL: https://ojrs.abvpress.ru/ojrs/article/view/106
- DOI: https://doi.org/10.17650/1994-4098-2012-0-2-82-88
- ID: 106
Cite item
Full Text
Abstract
Increasing survival of oncology patients depends on early diagnostics, developing the new technologies of the treatment and the new drugs. It allows finding out more and more patients with bone metastases. So the answers to the questions about bisphosphonate`s duration, complication of the treatment and improvement of quality of life are very necessary and important. We`ve analyzed long-term (1 year ) introduction of zoledronic acid 4 mg monthly in patients with breast cancer and bone metastasis. The data suggests that long-term treatment of zoledronic acid allows improving quality of life of this kind of patients.
Keywords
About the authors
O. V. Zelenova
Central Research Institute for Organization and Informatization of Health Care, Russian Ministry of Health
Author for correspondence.
Email: olga_verde@mail.ru
Russian Federation
L. V. Bolotina
P.A. Herzen Moscow Oncology Research InstituteRussian Federation
L. Yu. Nikitina
Orenburg Regional Clinical Oncology DispensaryRussian Federation
M. V. Chernikov
AO Aston Consulting, MoscowRussian Federation
References
Supplementary files
